Technical Analysis for DBTX - Decibel Therapeutics, Inc.

Grade Last Price % Change Price Change
F 7.96 -0.50% -0.04
DBTX closed down 0.5 percent on Wednesday, May 5, 2021, on 42 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Very Strong N/A Down Down
Historical DBTX trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Doji - Bullish? Reversal 0.00%
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Older End-of-Day Signals for DBTX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 9 hours ago
Down 2 % about 9 hours ago
Down 1% about 10 hours ago
Fell Below Previous Day's Low about 10 hours ago
60 Minute Opening Range Breakdown about 10 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Decibel Therapeutics, Inc. Description

Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin, or OTOF, gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy, or BVP, by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was founded in 2013 and is based in Boston, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Biology Chemotherapy Gene Therapy Occupational Safety And Health Hearing Audiology Hearing Loss Deafness Auditory System Balance Disorders Hair Cell

Is DBTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 24.39
52 Week Low 7.72
Average Volume 136,266
200-Day Moving Average 0.00
50-Day Moving Average 12.55
20-Day Moving Average 9.72
10-Day Moving Average 9.13
Average True Range 0.70
ADX 60.8
+DI 4.85
-DI 35.46
Chandelier Exit (Long, 3 ATRs ) 9.59
Chandelier Exit (Short, 3 ATRs ) 9.82
Upper Bollinger Band 11.31
Lower Bollinger Band 8.13
Percent B (%b) -0.06
BandWidth 32.67
MACD Line -1.16
MACD Signal Line -1.17
MACD Histogram 0.0132
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.73
Resistance 3 (R3) 8.73 8.48 8.60
Resistance 2 (R2) 8.48 8.29 8.48 8.55
Resistance 1 (R1) 8.22 8.16 8.35 8.22 8.51
Pivot Point 7.97 7.97 8.04 7.97 7.97
Support 1 (S1) 7.71 7.78 7.84 7.71 7.41
Support 2 (S2) 7.46 7.65 7.46 7.37
Support 3 (S3) 7.20 7.46 7.32
Support 4 (S4) 7.20